Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 12
2004 15
2005 18
2006 16
2007 12
2008 7
2009 5
2010 6
2011 3
2012 4
2013 9
2014 11
2015 6
2016 4
2017 17
2018 10
2019 8
2020 13
2021 22
2022 23
2023 18
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Drilon A, et al. Among authors: sakamoto t. N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653. N Engl J Med. 2020. PMID: 32846060 Free PMC article. Clinical Trial.
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome.
Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, Ako J, Arai H, Ishii H, Origuchi H, Shimizu W, Takemura H, Tahara Y, Morino Y, Iino K, Itoh T, Iwanaga Y, Uchida K, Endo H, Kongoji K, Sakamoto K, Shiomi H, Shimohama T, Suzuki A, Takahashi J, Takeuchi I, Tanaka A, Tamura T, Nakashima T, Noguchi T, Fukamachi D, Mizuno T, Yamaguchi J, Yodogawa K, Kosuge M, Kohsaka S, Yoshino H, Yasuda S, Shimokawa H, Hirayama A, Akasaka T, Haze K, Ogawa H, Tsutsui H, Yamazaki T; Japanese Circulation Society Joint Working Group. Kimura K, et al. Among authors: sakamoto t. Circ J. 2019 Apr 25;83(5):1085-1196. doi: 10.1253/circj.CJ-19-0133. Epub 2019 Mar 29. Circ J. 2019. PMID: 30930428 Free article. Review. No abstract available.
Authors' reply.
Inamori T, Sakamoto T. Inamori T, et al. Among authors: sakamoto t. J Cardiol Cases. 2022 Apr 1;26(2):162-163. doi: 10.1016/j.jccase.2022.03.007. eCollection 2022 Aug. J Cardiol Cases. 2022. PMID: 35949575 Free PMC article. No abstract available.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: sakamoto t. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y, Kubota K, Shimokawa M, Hashimoto K, Kawashima Y, Sakamoto T, Wakui H, Murakami S, Okishio K, Hayashihara K, Ohe Y; Tokyo Cooperative Oncology Group (TCOG). Okuma Y, et al. Among authors: sakamoto t. JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013. JAMA Oncol. 2024. PMID: 37991747
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: sakamoto t. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Clinical Trial.
Multiplex gene-panel testing for lung cancer patients.
Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Yatabe Y, et al. Among authors: sakamoto t. Pathol Int. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. Epub 2020 Sep 21. Pathol Int. 2020. PMID: 32956529 Review.
Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, Sakamoto T, Murakami H, Kishimoto J, Matsumoto S, Nakanishi Y, Goto K, Okamoto I. Iwama E, et al. Among authors: sakamoto t. Eur J Cancer. 2022 Feb;162:99-106. doi: 10.1016/j.ejca.2021.11.021. Epub 2021 Dec 24. Eur J Cancer. 2022. PMID: 34959152 Clinical Trial.
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Haratake N, Hayashi H, Shimokawa M, Nakano Y, Azuma K, Oki M, Ota K, Yoshioka H, Sakamoto T, Yamamoto N, Nakagawa K, Seto T. Haratake N, et al. Among authors: sakamoto t. Clin Lung Cancer. 2022 May;23(3):e257-e263. doi: 10.1016/j.cllc.2021.10.007. Epub 2021 Oct 24. Clin Lung Cancer. 2022. PMID: 34887192 Clinical Trial.
216 results